European legislative initiatives such as the Biotech Act, the MDR/IVDR revision, the Critical Medicines Act, the new European pharmaceutical legislation and measures relating to online health information will have a significant impact on all stakeholders. The FAMHP provides an update on the current situation. Even though the initiatives mentioned cover a wide range of areas, they share a common ambition: to strengthen a coherent and workable European regulatory framework that fosters innovation, safeguards patient safety and supports sustainable access to medicines and health products. The FAMHP remains actively committed to developing and implementing Belgium’s positions in European forums, with particular attention to striking a balance
FAMHP (Belgian Medicine Agency) · July 07, 2026
Future European legislation: state of play
FAMHP updates on pending EU legislative initiatives including Biotech Act, MDR/IVDR revision, Critical Medicines Act, pharmaceutical legislation, and online health information measures.
Published by FAMHP (Belgian Medicine Agency). HealthSignal links to the original document; the summary above is extracted from the source text.